Biogaia
BioGaia AB, commonly referred to as BioGaia, is a leading biotechnology company headquartered in Sweden. Founded in 1990, the company has established itself as a pioneer in the development of probiotic products, focusing on gut health and overall well-being. With a strong presence in Europe, North America, and Asia, BioGaia operates within the health and wellness industry, specifically in the probiotics sector. The company’s core offerings include a range of probiotic supplements and functional foods, distinguished by their unique strains of Lactobacillus reuteri. BioGaia's commitment to scientific research and innovation has led to numerous key milestones, including partnerships with major global brands and a robust portfolio of clinical studies supporting their products. Recognised for its market leadership, BioGaia continues to enhance its reputation through ongoing advancements in probiotic technology and consumer education.
DitchCarbon Score
How does Biogaia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biogaia's score of 51 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Biogaia's reported carbon emissions
In 2023, BioGaia AB reported total greenhouse gas emissions of approximately 7,257,000 kg CO2e. This figure includes 77,000 kg CO2e from Scope 1 emissions, which primarily arise from mobile combustion, and 32,000 kg CO2e from Scope 2 emissions, associated with purchased electricity. The majority of their emissions, approximately 6,148,000 kg CO2e, fall under Scope 3, which encompasses indirect emissions from sources such as business travel and purchased goods and services. BioGaia has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 emissions by 46% by 2030, using 2019 as the baseline year. This target has been validated by the Science Based Targets initiative (SBTi) and aligns with the necessary reductions to limit global warming to 1.5°C. The company is also committed to measuring and reducing its Scope 3 emissions, reflecting a comprehensive approach to tackling its carbon footprint. Overall, BioGaia's proactive stance on climate action demonstrates its commitment to sustainability within the pharmaceuticals and biotechnology sector, headquartered in Sweden.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 9,000 | 0,000 | 00,000 | 00,000 | 00,000 |
| Scope 2 | 69,000 | 00,000 | 0,000 | 00,000 | 00,000 |
| Scope 3 | 2,609,000 | 0,000,000 | 00,000 | 00,000 | 00,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biogaia is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
